Both CV mortality and major bleeding were rarer when antiplatelets weren’t added, with no tradeoff in ischemic events.

The vast majority of patients presenting with type 1 NSTEMI undergo invasive coronary angiography in the US, with most receiving PCI, according to an analysis presented this week at CRT 2026. But as ...

At 3 years, Agent still outshined uncoated balloons. Registry data show rapid uptake of the DCB in the year after its FDA approval.

Barbara Casadei talks with host Yael L. Maxwell about tackling her new role as Editor-in-Chief of JAMA Cardiology as well as changing priorities throughout her career.

In hypothetical situations, physicians chose intensive treatment more often if BP and mobility metrics were available.

Operative mortality fell over time, but there was a concerning uptick in recent years attributed to low-volume sites.

There was a consensus that more data are needed to answer this question, with discussions about what such a trial would look like.

Outcomes and expenses were similar with transplant and elective LVAD, but urgent LVAD after ECMO fared much worse.

Patients already had high NT-proBNP levels at baseline, though, raising questions about the quality of GDMT, Nancy Sweitzer ...

PE or PEERLESS, the choice of therapy was shifting, influenced by patient factors and institutional protocols.

The study emphasizes the importance of vigilance with diet and exercise, among other things, to reduce CV risk in type 2 diabetes.

Amid late-breaking coronary, structural, and endovascular trials will be a keynote from President Biden, and more.